Q1 2026 earnings snapshot sets up margins story for Travere Therapeutics (TVTX)

Travere Therapeutics (TVTX) heads into its Q1 2026 update with recent quarterly revenue of US$129.7 million in Q4 2025 and basic EPS of US$0.29 in Q3 2025 giving way to a loss of US$0.24 per share in Q4, alongside trailing 12 month revenue of US$490.7 million and a net loss of US$50.3 million. Over the past year, revenue has moved from US$233.2 million on a trailing 12 month basis in Q4 2024 to US$490.7 million in Q4 2025. Over the same period, basic EPS shifted from a loss of US$4.06 to a loss of US$0.56, putting the spotlight firmly on how Q1 margins and loss levels evolve from here.

See our full analysis for Travere Therapeutics.

With the latest results on the table, the next step is to see how these reported revenue and EPS trends line up with the stronger growth story many investors have been following, and where the narrative might need an update.

Losses shrink on trailing basis but Q4 swings back into the red

• On a trailing 12 month basis, Travere reported a net loss of US$50.3 million and basic EPS of US$0.56 loss in Q4 2025, compared with quarterly net income of US$25.7 million and basic EPS of US$0.29 in Q3 2025. This shows that the year as a whole still ended in loss making territory even after a profitable quarter.
• Bulls emphasise a path toward stronger profitability, and the data partly lines up with that view but also shows where work is still needed.
  • The bullish narrative talks about earnings potentially reaching hundreds of millions of US dollars over time. The trailing 12 month loss of US$50.3 million and three loss making quarters in 2025 remind you that recent performance is still firmly in investment mode.
  • At the same time, moving from a trailing 12 month basic EPS loss of US$4.06 in Q4 2024 to US$0.56 loss in Q4 2025 is consistent with the idea that losses are being reduced. This is one of the key bullish talking points.

Bulls argue this improving earnings profile could be the early stage of the profitability shift they are betting on, and lay out what that upside might look like in more detail in the 🐂 Travere Therapeutics Bull Case.

Revenue ramp and product focus sit at the center of the debate

• Trailing 12 month revenue moved from US$233.2 million in Q4 2024 to US$490.7 million in Q4 2025, with quarterly revenue in 2025 ranging from US$81.7 million in Q1 to US$164.9 million in Q3 and US$129.7 million in Q4. This means most of the top line now comes from the new rare kidney disease portfolio rather than older products.
• Critics focus on reliance on a narrow set of therapies, and the revenue mix in the data gives them both support and a clear test.
  • The bearish narrative highlights heavy dependence on FILSPARI and a few rare disease drugs. The jump in trailing 12 month revenue to US$490.7 million with several products in late stage development shows how concentrated recent growth has been in this kidney disease franchise.
  • On the other hand, having 3 products in Phase III and 1 in pre registration at the trailing 12 month Q4 2025 point adds pipeline breadth that directly matters for that bearish concern about over reliance on a single product line.

Skeptics point to this concentrated revenue surge as a reason to be cautious about durability, and set out how that feeds into their view in the 🐻 Travere Therapeutics Bear Case.

Valuation gap, forecasts and current price do not tell the same story

• Travere trades at a P/S of 8.4x compared with 10.8x for the wider US Biotechs group and 12.3x for peers, and the current share price of US$44.80 sits below both the DCF fair value of US$84.25 and the single allowed analyst price target of US$52.64. This frames a potential valuation gap against both fundamentals based and market based references.
• What stands out when comparing this to the balanced analyst narrative is how much of that gap depends on future execution rather than the last 12 months.
  • The consensus narrative talks about revenue growing around 33.3% a year and margins turning from a roughly 10.2% loss to 26.5% profit, while the trailing 12 month figures still show a US$50.3 million loss. Any upside implied by the DCF fair value of US$84.25 or the US$52.64 analyst target relies on that shift actually occurring.
  • At the same time, the reduction in trailing 12 month losses over the past five years at about 4% a year matches the idea that the business is moving toward breakeven. This is part of why some investors see the current 8.4x P/S multiple as lower than the long term growth profile might eventually support.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Travere Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all this in mind, do the recent results leave you feeling cautious or optimistic about the margin story ahead? Take a moment to look through the numbers yourself, compare them with your expectations, and then weigh up the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Travere is still reporting a trailing 12 month loss of US$50.3 million with three loss making quarters in 2025 and margins yet to turn sustainably positive.

If that level of ongoing loss and execution risk feels uncomfortable, you can quickly compare it with companies screened for stronger finances using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.